during the reporting period, fosun pharma achieved steady growth as the revenue increased by 6.02% yoy, to rmb30,307 million; the net profit attributable to shareholders of the listed company amounted to rmb3,663 million, representing an increase of 10.27% yoy; the net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss amounted to rmb2,718 million, representing an increase of 21.65% yoy. during the reporting period, the group’s core business, the pharmaceutical manufacturing segment, realized revenue of rmb21,880 million. the medical devices and medical diagnosis segment realized revenue of rmb5,217 million. the healthcare services segment realized revenue of rmb3,172 million.